Scrip Asks… What's The Current Climate For Deal-Making? (Part 1)
Following Gilead's acquisition of Kite, buzz grew that the deal might catalyze a surge in deal-making. Scrip asked a broad cross-section of biopharma insiders and observers about the deal-making environment – first up are responses from small biotechs.
You may also be interested in...
Celgene splashes $150m to buy a stake in BeiGene of China and $263m upfront to get rights to a PD-1 antibody that could catapult the US firmly up the immuno-oncology ladder.
Allergan will pay $2.9bn in cash for LifeCell, a division of Acelity, adding its first regenerative medicine portfolio and marking its first commercial-stage deal in more than a year. The company hopes to exploit the surgical products for aesthetic uses beyond breast reconstruction.
Looking back at the deal landscape of 2020, large-scale deals were overtaken by smaller transactions, though volume was up, driven by pandemic-related business.